Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved

BACKGROUND: Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. CASE PRESENTATION: We discuss t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saita, Chiaki, Goto, Risa, Aruga, Tomoyuki, Idera, Nami, Honda, Yayoi, Horiguchi, Kazumi, Miyamoto, Hiromi, Horiguchi, Shinichiro, Yamashita, Toshinari, Kuroi, Katsumasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727271/
https://www.ncbi.nlm.nih.gov/pubmed/26813772
http://dx.doi.org/10.1186/s13104-016-1854-4
Descripción
Sumario:BACKGROUND: Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. CASE PRESENTATION: We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. CONCLUSION: Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.

Ejemplares similares